Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Fisioterapeutas en oncología October 12, 2021 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 New lung cancer treatment combo approved on NHS in England January 12, 2022 Load more HOT NEWS Can Chemotherapy Drugs Be Designed to Avoid Side Effects? T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... EMA Recommends Extension of Indications for Niraparib
